Omvoh

Eli Lilly reports durable four-year efficacy data for Omvoh in IBD, with 63.5% ulcerative colitis remission and 92.4% Crohn's response rates, bolstering pipeline confidence.

Eli Lilly's Omvoh shows durable three-year remission in Crohn's disease, with 92.4% of patients maintaining clinical remission and reduced hospitalizations compared to placebo.